Corvus Pharmaceuticals, Inc. (CRVS)의 가격은 얼마입니까?

Corvus Pharmaceuticals, Inc. (CRVS)의 가격은 $14.07입니다.

Corvus Pharmaceuticals, Inc. (CRVS)의 시가 총액은 무엇입니까?

Corvus Pharmaceuticals, Inc. (CRVS)의 시가 총액은 $1.18B입니다.

Corvus Pharmaceuticals, Inc. (CRVS) 배당수익률

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

연도	배당 수익률	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

배당 수익률

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	배당 수익률	국가
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	3.12%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

회사

배당 수익률

국가